SoftOx Solutions AS

SoftOx Solutions AS has a liquidity position that appears to be strong, with a current ratio of 1.8, indicating that the company has 1.8 NOK in current assets for every 1 NOK in current liabilities. The company holds 19.8 million NOK in cash and equivalents, which is a significant portion of its total assets of 33.9 million NOK. However, the company's operating cash flow is negative at -18.9 million NOK, and its free cash flow is also negative at -7.6 million NOK, suggesting that it is not generating sufficient cash from operations to sustain its activities without external financing.

In terms of profitability, SoftOx Solutions AS is currently unprofitable, with a net loss of 10.8 million NOK and an operating loss of 11.4 million NOK. The company's return on equity is -47.1%, and its return on assets is -31.9%, both of which are significantly below the industry median for biotechnology and medical research firms. These metrics indicate that the company is not effectively utilizing its equity or assets to generate returns.

The company's revenue is not segmented by product or geographic region in the available data, so it is not possible to determine the concentration of its revenue sources. However, the lack of segmentation suggests that the company may be heavily reliant on a few key products or markets, which could expose it to higher risk if those products or markets experience a downturn.

Looking at the company's growth trajectory, there is no available outlook data for the current or next fiscal year, so it is not possible to determine the direction of its revenue or earnings. The company's historical revenue of 15.6 million NOK is the only data point available, and without additional information, it is difficult to assess whether the company is growing or declining.

The risk assessment for SoftOx Solutions AS indicates that the company has low liquidity and dilution risk, with no immediate filing-based flags detected. However, the company's negative operating and free cash flows suggest that it may need to raise additional capital in the future, which could lead to dilution for existing shareholders. The company's debt-to-equity ratio of 0.45 is relatively low, indicating that it is not heavily leveraged.

There are no recent events or filings mentioned in the available data, so it is not possible to determine whether the company has experienced any significant developments in the near term. The lack of recent events may indicate that the company is in a stable but uneventful phase of its operations.